Any current/future new fundraising through debt or equity?

The company has a healthy cash balance of Rs. 1.3 billion and strong cash generation. Significant capital expenditure (CAPEX) planned for expansions, including: - Acetonitrile plant costing around Rs. 150-160 crores (already mostly spent by March 2021). - Aliphatic Amines plant at Kurkumbh estimated at Rs. 300-350 crores. CAPEX will absorb much of the company's cash reserves. They plan to acquire new land (50-100 acres) around FY 2022-23 for future growth, requiring substantial investment. There is no explicit mention of current or planned fundraising through external debt or equity. The c

Any current/future capex/capital investment/strategic investment?

Ongoing Acetonitrile plant expansion, costing Rs.150-160 crores, expected completion by October 2021 (delayed due to COVID). FY'21 CAPEX spent approximately Rs.140-150 crores; planned CAPEX of around Rs.200 crores in FY'22. New Aliphatic Amines plant at Kurkumbh with utilities, a near Greenfield project, estimated at Rs.300-350 crores; expected completion by mid to third quarter of FY'22-23. Additional CAPEX of about Rs.200 crores planned for FY'23, possibly more. Exploring acquisition of new land (around 50-100 acres) in FY'22-23 for future growth, as current sites' expansions will be used up

Future growth expectations in sales/revenue/volumes?

The company expects volume growth on the higher side of 15% annually over the medium term (3 to 5 years), with some variation in individual years. New capacity installations, such as the Acetonitrile plant commissioning, are expected to cause volume spurts. Continued growth is driven primarily by demand from the expanding Indian pharmaceutical industry and other sectors like agrochemicals. Domestic market growth is robust, partly offsetting international competition effects. The company foresees no upper limit to growth due to reinvestment in capacity and expansion plans. Debottlenecking exist

Future growth expectations in earnings/operating earnings/profits/EPS?

Volume growth expected at the higher side of 15% over the medium term (3-5 years), with some fluctuations in certain years. New capacity commissioning (e.g., Acetonitrile plant expected second half of FY21-22) to provide volume growth spurts. Indian pharmaceutical industry growth and low penetration levels support sustained demand for Alkyl Amines' products. Continuous capacity debottlenecking and new greenfield plants planned to accommodate growth. EBITDA margins have structurally improved, unlikely to revert to older lower levels, but future margin sustainability depends on raw material pric

Alkyl Amines Chemicals LtdQ4 FY21Chemicals & Petrochemicals

Alkyl Amines Chemicals Ltd Q4 FY21 Earnings Call Analysis

Revenue, margin, capex, fundraise and order book outlook from management commentary.

Price: ₹1,653.8P/E: 37.6Market Cap: ₹8.5K CrSector: Chemicals & Petrochemicals

Management growth scorecard

Revenue

Category 3

Margin

Category 3

Fundraise

N/A

Order

N/A

Capex

Yes

1 of 3 growth signals are positive — mixed outlook.

Full analysis

Revenue guidance

Category 3

The company expects volume growth on the higher side of 15% annually over the medium term (3 to 5 years), with some variation in individual years.
New capacity installations, such as the Acetonitrile plant commissioning, are expected to cause volume spurts.
Continued growth is driven primarily by demand from the expanding Indian pharmaceutical industry and other sectors like agrochemicals.
Domestic market growth is robust, partly offsetting international competition effects.
The company foresees no upper limit to growth due to reinvestment in capacity and expansion plans.
Debottlenecking existing plants provides additional capacity, but new greenfield plants are also planned to meet rising demand.
Strategic capital expenditure plans include new aliphatic amine plants and expansions in key product lines to capture market share and reduce import reliance.

Margin guidance

Category 3

Volume growth expected at the higher side of 15% over the medium term (3-5 years), with some fluctuations in certain years.
New capacity commissioning (e.g., Acetonitrile plant expected second half of FY21-22) to provide volume growth spurts.
Indian pharmaceutical industry growth and low penetration levels support sustained demand for Alkyl Amines' products.
Continuous capacity debottlenecking and new greenfield plants planned to accommodate growth.
EBITDA margins have structurally improved, unlikely to revert to older lower levels, but future margin sustainability depends on raw material prices and the ability to pass on costs.
CAPEX of Rs. 200 crore in FY21-22 and Rs. 300-350 crore for the new aliphatic amines plant planned.
New land acquisition planned in FY22-23 for further expansion, indicating growth ambitions.
Earnings and profitability are expected to grow, though margin levels may fluctuate due to raw material price volatility.

See what Alkyl Amines Chemicals Ltd management said on margin guidance — free account, 30 seconds.

Fundraise plans

The company has a healthy cash balance of Rs. 1.3 billion and strong cash generation.
Significant capital expenditure (CAPEX) planned for expansions, including:
- Acetonitrile plant costing around Rs. 150-160 crores (already mostly spent by March 2021).
- Aliphatic Amines plant at Kurkumbh estimated at Rs. 300-350 crores.
CAPEX will absorb much of the company's cash reserves.
They plan to acquire new land (50-100 acres) around FY 2022-23 for future growth, requiring substantial investment.
There is no explicit mention of current or planned fundraising through external debt or equity.
The company appears to be funding expansions primarily through internal accruals and cash on hand.

Order book

The provided transcript from the Alkyl Amines Chemicals Limited earnings call dated May 28, 2021, does not mention any details regarding the current or expected order book or pending orders. The discussion primarily focuses on: - EHS initiatives and ZLD facility timelines - Capacity expansions and CAPEX plans - Volume growth expectations and market outlook - Margin sustainability and pricing pressures - Customer relationships and repeat business - Challenges due to COVID-19 impact No specific information about order book status or pending orders is provided in the text.

See what Alkyl Amines Chemicals Ltd management said on order book — free account, 30 seconds.

Capex plans

Yes

Ongoing Acetonitrile plant expansion, costing Rs.150-160 crores, expected completion by October 2021 (delayed due to COVID).
FY'21 CAPEX spent approximately Rs.140-150 crores; planned CAPEX of around Rs.200 crores in FY'22.
New Aliphatic Amines plant at Kurkumbh with utilities, a near Greenfield project, estimated at Rs.300-350 crores; expected completion by mid to third quarter of FY'22-23.
Additional CAPEX of about Rs.200 crores planned for FY'23, possibly more.
Exploring acquisition of new land (around 50-100 acres) in FY'22-23 for future growth, as current sites' expansions will be used up in the next three years.
Plan to expand capacity by around 30% in Aliphatic Amines.
Post-expansion, debottlenecking exercises will continue to optimize capacities.
New expansions being planned with Zero Liquid Discharge (ZLD) facilities in mind.

Track Alkyl Amines Chemicals Ltd — get its next earnings analysis in your feed

How does Alkyl Amines Chemicals Ltd rank vs peers in Chemicals & Petrochemicals?

Pro feature

ThisAlkyl Amines Chemicals Ltd

Rev 3Mar 3

See where Alkyl Amines Chemicals Ltd sits in Chemicals & PetrochemicalsSee which companies these are, and every other name in the sector.Open rankings

How does Alkyl Amines Chemicals Ltd rank in Chemicals & Petrochemicals?

Compare Alkyl Amines Chemicals Ltd against every Chemicals & Petrochemicals company (Q4 FY21) on revenue, margins and earnings-call signals.

View Chemicals & Petrochemicals leaderboard →

What Alkyl Amines Chemicals Ltd's management said in earlier quarters

Others in Chemicals & Petrochemicals this season

Alufluoride Ltd (Q1 FY27)
Revenue from operations for Q1 FY27 was ₹26.6 crore, down 39% YoY (Page 6, 7, 8). Key investor presentation takeaways from Alufluoride Ltd's Q1 FY27 investor pr
POCL Enterprises Ltd (Q1 FY27)
466.03 crores (Page 12, 17, 11) . Key investor presentation takeaways from POCL Enterprises Ltd's Q1 FY27 investor presentation — and how it ranks against secto
Deepak Nitrite Ltd (Q2 FY27)
Q2 FY27 total revenue: ₹3,091 crore, up 61% YoY (Page 1, 4, 5, 6, 10, 11) . Key investor presentation takeaways from Deepak Nitrite Ltd's Q2 FY27 investor prese
Privi Speciality Chemicals Ltd (Q2 FY27)
19,239.47 lakhs (approximately 33.9% growth). Key results statement takeaways from Privi Speciality Chemicals Ltd's Q2 FY27 results statement — and how it ranks

Compare:vs Solar Industries vs Pidilite Inds.vs SRF Ltd

🔎 Who's planning the most growth?

Companies ranked by management's own guidance — revenue, margins, capex and order book, from every earnings call in India.

See rankings →

Alkyl Amines Chemicals Ltd Q4 FY21 Earnings Call Analysis

Revenue guidance

Fundraise plans

Capex plans

How does Alkyl Amines Chemicals Ltd rank in Chemicals & Petrochemicals?

Continue your research

What Alkyl Amines Chemicals Ltd's management said in earlier quarters

Others in Chemicals & Petrochemicals this season